Recent Updates
Recently added Catalysts

MK-1708

Phase 1

Healthy | Small molecule | Other |Merck & Company, Inc.|Last Updated: May 15, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment16
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06647628A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)PHASE1 COMPLETED 16 — — Nov 4, 2024Mar 31, 2025May 15, 20251 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participants with ≥1 adverse event (AE)
Up to 14 days after the last dose
Number of participants discontinuing study therapy due to AE
Up to ~2 weeks
Area under the plasma concentration-time curve from dosing to 24 hours postdose (AUC0-24) of multiple MK-1708 doses
At designated time points up to ~2 weeks
Maximum plasma concentration (Cmax) of multiple MK-1708 doses
At designated time points up to ~20 days
Time to maximum plasma concentration (Tmax) of multiple MK-1708 doses
At designated time points up to ~20 days
Concentration 24 hours postdose (C24) of multiple MK-1708 doses
At designated time points up to ~2 weeks
Apparent oral clearance (CL/F) of multiple MK-1708 doses, at steady state
At designated time points up to ~20 days
Apparent volume of distribution (Vz/F) of multiple MK-1708 doses, at steady state
At designated time points up to ~20 days
Apparent terminal half-life (t½) of multiple MK-1708 doses
At designated time points up to ~20 days
AUC0-24 accumulation ratio of multiple MK-1708 doses
At designated time points up to ~2 weeks
Cmax accumulation ratio of multiple MK-1708 doses
At designated time points up to ~20 days
C24 accumulation ratio of multiple MK-1708 doses
At designated time points up to ~2 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
MK-1708 Dosage 1EXPERIMENTALParticipants receive multiple doses of MK-1708 dosage 1.
MK-1708 Dosage 2EXPERIMENTALParticipants receive multiple doses of MK-1708 dosage 2.
PlaceboPLACEBO_COMPARATORParticipants receive multiple doses of placebo.
Interventions
NameTypeDescription
MK-1708DRUGMK-1708 oral suspension
PlaceboDRUGPlacebo oral suspension
Unlock Study Design Details
Eligibility Criteria
Age Range65 Years — 85 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a...

Countries:United States
Unlock Eligibility Criteria